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ABSTRACT
Pancreatic cancer is a highly malignant tumor type with poor outcomes, and 
elucidation of the mechanisms involved in cancer progression and therapeutic 
resistance is critical. FBXW7 is a key regulator of tumor malignant potential, and its 
substrate MCL1 regulates therapeutic resistance in human malignancies. Therefore, 
determination of the relevance of FBXW7 expression is critical for improving patient 
outcomes. In this study, we investigated the function and clinical significance of FBXW7 
in pancreatic cancer. FBXW7 expression was evaluated by immunohistochemistry 
in 122 pancreatic cancer tissues. Reduced FBXW7 expression was significantly 
associated with advanced venous invasion, high MCL1 expression, enhanced Ki-67 
expression, and poor prognosis and was an independent poor prognostic factor. 
Among patients who underwent gemcitabine treatment after surgery, reduced 
FBXW7 expression was also significantly associated with poor prognosis. Knockdown 
of FBXW7 in vitro enhanced cell proliferation, and migration, and invasion abilities 
and promoted gemcitabine and nab-paclitaxel chemoresistance in pancreatic cancer 
cells. Moreover, FBXW7-knockdown cells showed accumulation of MCL1, and the 
enhanced chemoresistance observed in FBXW7-knockdown cells was eliminated by 
MCL1 suppression. These results suggested that FBXW7 was associated with cancer 
progression and mediated sensitivity to gemcitabine and nab-paclitaxel via MCL1 
accumulation in pancreatic cancer. Thus, the FBXW7/MCL1 axis may be a promising 
therapeutic tool to overcome refractory pancreatic cancer.
INTRODUCTION
Pancreatic cancer is a highly malignant tumor type 
with poor outcomes; the 5-year overall survival rate, 
including unresectable and metastatic cancer, is less 
than 10% [1, 2]. Although multidisciplinary treatment, 
including new chemotherapy, such as gemcitabine plus 
nab-paclitaxel [3] and FOLFIRINOX [4], is generally 
performed, the incidence of pancreatic cancer remains 
nearly equal to its mortality rate. Pancreatic cancer is 
characterized by rapid progression, early metastasis, 
and limited response to chemotherapy and radiotherapy 
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[5]. Therefore, to improve the prognosis of patients 
with pancreatic cancer, it is important to elucidate the 
mechanisms underlying therapeutic resistance and 
develop new therapeutic targets.
F-box and WD repeat domain-containing 7 
(FBXW7), which is a substrate recognition subunit of 
the Skp1-Cul1-F box ubiquitin ligase complex, is a 
key regulator of proliferation, invasion, apoptosis, and 
chemotherapeutic resistance in human malignancies and 
functions via the degradation of oncoproteins, including 
c-Myc and myeloid leukemia cell differentiation 
protein (MCL1), in a proteasome-dependent manner 
[6, 7]. Thus, FBXW7 is considered an important tumor 
suppressor in various cancers [8]. In clinical samples, 
reduced expression of FBXW7 has been reported to be 
associated with poor prognosis and cancer progression 
in various human solid cancers, such as gastric cancer 
[9], esophageal cancer [10], colorectal cancer [11], and 
cholangiocarcinoma [12, 13], due to the accumulation 
of several oncoproteins. In pancreatic cancer, a recent 
report showed that Ras/Raf/MEK/ERK activation 
induced by KRAS mutations, which are frequently 
observed in pancreatic cancer, plays important roles 
in reducing FBXW7 expression [14]. ERK directly 
phosphorylates FBXW7, which leads to the self-
ubiquitination and proteosomal degradation of FBXW7 
itself. This low FBXW7 protein expression results 
in accumulation of multiple FBXW7 substrates in 
pancreatic cancer. Moreover, although the mechanisms 
regulating FBXW7 expression are gradually being 
elucidated, studies on the impact of FBXW7 expression 
and its substrate in pancreatic cancer are limited.
MCL1, which is a target of FBXW7 and a member 
of the BCL2 protein family, is an anti-apoptotic protein 
that has been reported to be overexpressed in pancreatic 
cancer cells and clinical tissue samples and is correlated 
with advanced disease [15]. Furthermore, recent studies 
have suggested that MCL1 regulates not only apoptotic 
cell death but also responses to certain chemotherapeutic 
agents, particularly antitubulin chemotherapy [16, 
17]. Therefore, it is important to investigate the role 
of FBXW7 expression, which regulates MCL1, in 
pancreatic cancer.
Accordingly, the aim of this study was to identify 
the function and clinical significance of FBXW7 in 
pancreatic cancer. In the present study, we examined 
FBXW7 expression in 122 pancreatic cancer tissues 
using immunohistochemistry to clarify the clinical 
significance of FBXW7 expression. Moreover, the 
effects of FBXW7 downregulation by RNA interference 
(RNAi) were examined in pancreatic cancer cells to 
evaluate whether FBXW7 played important roles in 
proliferation, migration, invasion, and chemoresistance. 
Furthermore, we demonstrated MCL1 is a key substrate 
of FBXW7 involved in chemotherapeutic resistance in 
pancreatic cancer.
RESULTS
Immunohistochemical analysis of FBXW7 
expression in patients with pancreatic cancer
FBXW7 expression was immunohistochemically 
evaluated in 122 pancreatic cancer tissues and was found to 
be mainly expressed in the nucleus. Hence, we performed 
nuclear staining of cancer cells as for determining FBXW7 
expression. Nuclear FBXW7 expression in cancer tissues 
tended to be lower than that in adjacent noncancerous 
tissues (Figure 1A). Additionally, FBXW7 expression 
at the cancer invasion front was lower than that in the 
center of the primary tumor (Figure 1B). In this study, 68 
samples were included in the high FBXW7 expression 
group (Figure 1C), and 54 samples were included in the 
low FBXW7 expression group (Figure 1D). 
Clinical significance of nuclear FBXW7 
expression in patients with pancreatic cancer
The associations between clinicopathological 
characteristics and FBXW7 expression are presented 
in Table 1. Low FBXW7 expression was significantly 
associated with higher venous invasion (P = 0.037), 
and a similar trend was observed in lymphatic invasion, 
although the difference was not significant (P = 0.081). 
Furthermore, the expression levels of FBXW7 and MCL1 
were significantly inversely correlated (P = 0.032). Thus, 
Low FBXW7 expression was associated with high MCL1 
expression. Representative relationships between FBXW7 
and MCL1 expression are shown in Supplementary 
Figure 1. Samples with low FBXW7 expression showed 
enhanced MCL1 expression (Supplementary Figure 1A), 
whereas samples with high FBXW7 expression showed 
decreased MCL1 expression (Supplementary Figure 1B). 
Next, Ki-67 expression was evaluated to validate 
the relationships between FBXW7 expression and 
proliferation potential. The proportion of Ki-67-positive 
cells as a proliferation marker was significantly higher 
in the low FBXW7 expression group than in the high 
FBXW7 expression group (P = 0.026). Additionally, 
localization of nuclear FBXW7 expression and Ki-
67 expression was inversely correlated, as shown by 
evaluating sequential sections of tissue samples by 
immunohistochemistry (Supplementary Figure 2). 
The association between prognosis and FBXW7 
expression was evaluated by the Kaplan-Meier method. 
The overall survival and cancer-specific survival rates 
were significantly lower in patients with low FBXW7 
expression than in patients with high FBXW7 expression 
(P = 0.009 and P = 0.001, respectively; Figure 2A, 
B). Similarly, the relapse-free survival rate was also 
significantly lower in patients with low FBXW7 expression 
(P = 0.036; Figure 2C). Furthermore, we evaluated the 
influence of chemotherapy with gemcitabine, a major 
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drug for pancreatic cancer chemotherapy, on prognosis 
according to FBXW7 expression. A total of 95 patients 
received chemotherapy as an adjuvant chemotherapy 
or to treat recurrence, and 27 patients did not receive 
chemotherapy. In patients who underwent gemcitabine 
treatment, the overall survival rate in the low FBXW7 
Table 1: Clinicopathological characteristics according to FBXW7 expression in 122 pancreatic 
cancer samples
Factors
FBXW7 expression
p-value
High (n = 68) Low (n = 54)
Age, median (range) 69 (36–87) 69 (36–82) 0.299 
Sex 0.166 
 Male 33 33
 Female 35 21
Histological type 0.521 
 Well 10 6
 Moderately, Poorly 49 42
T factor (UICC) 0.343 
 T1, 2 7 3
 T3, 4 61 51
Tumor size 0.907 
 ≤ 40 mm 51 40
 > 40 mm 17 14
Lymph node metastasis 0.432 
 Absent 18 11
 Present 50 43
Venous invasion 0.037*
 v0, 1 35 18
 v2, 3 32 36
Lymphatic invasion 0.081 
 ly0, 1 38 22
 ly2, 3 29 32
Perineural invasion 0.377 
 ne0, 1 21 13
 ne2, 3 46 41
TNM stage (UICC) 0.546 
 I, IIA 17 11
 IIB, III, IV 51 43
Reccurence 0.510 
 Absent 20 13
 Present 48 41
MCL1 expression 0.032*
 Low 47 27
 High 21 27
Ki-67 index, median (range) 38 (0-134) 62 (3-344) 0.026*
Abbreviations: UICC, Union for International Cancer Center.
*p < 0.05.
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expression group was significantly shorter than that in 
the high expression group (P = 0.007; Figure 2D). These 
data suggested that low nuclear expression of FBXW7 in 
cancer tissue may be related to chemoresistance.
Next, we evaluated the significance of FBXW7 
expression as a prognostic factor using the Cox 
proportional hazards model. Univariate and multivariate 
analyses for overall survival are show in Table 2. 
Univariate analysis showed that low FBXW7 expression 
was a poor prognostic factor (P = 0.011), as were 
histological type (P = 0.031), T factor (P = 0.001), and 
venous invasion (P < 0.0001). Multivariate analysis 
showed that low FBXW7 expression was an independent 
prognostic factor of poor survival (hazard ratio [HR] 
= 1.72; 95% confidence interval [CI] = 1.06–2.79; P = 
0.029), similar to existing clinicopathological factors, 
such as venous invasion (P = 0.003). Similarly, univariate 
and multivariate analyses for relapse-free survival also 
showed that low FBXW7 expression was an independent 
prognostic factor (HR = 1.55; 95% CI = 1.01–2.37; P = 
0.047, Supplementary Table 1).
RNAi targeting FBXW7 enhanced proliferation, 
migration, invasion, and chemoresistance and 
caused MCL1 accumulation in pancreatic cancer 
cells 
FBXW7 protein was expressed in SUIT-2 pancreatic 
cancer cells. We then knocked down FBXW7 expression 
in SUIT-2 cells by transfection with FBXW7-specific 
siRNA. FBXW7 suppression was confirmed by western 
blotting (Figure 3A). The proliferation ability of FBXW7-
knockdown cells was significantly enhanced in comparison 
with that in cells transfected with control siRNA (Figure 3B). 
Additionally, FBXW7-knockdown cells showed enhanced 
cell migration and invasion compared with control cells 
(Figure 3C, 3D). Analysis of the relationship between 
FBXW7 expression and chemotherapy with gemcitabine 
in clinical samples showed that FBXW7 expression may be 
related to chemosensitivity. 
We next evaluated the effects of FBXW7 knockdown 
on resistance to gemcitabine and nab-paclitaxel, which are 
used in first-line chemotherapy regimens for patients with 
advanced pancreatic cancer. FBXW7-knockdown cells 
showed enhanced resistance to both gemcitabine and nab-
paclitaxel compared with control cells (Figure 3E, 3F). 
Furthermore, the anti-apoptotic protein MCL1, which 
is a degradation substrate of FBXW7, was evaluated by 
western blotting. The results showed that MCL1 was 
accumulated in FBXW7-knockdown cells in comparison 
with control cells (Figure 3A).
The enhanced gemcitabine and nab-paclitaxel 
resistances in FBXW7-knockdown cells were 
eliminated by MCL1 suppression 
Next, to evaluate whether enhanced chemoresistance 
to gemcitabine and nab-paclitaxel in FBXW7-knockdown 
Figure 1: Immunohistochemical staining of FBXW7 in pancreatic cancer tissue. (A) FBXW7 expression was observed in the 
nuclei of cells. FBXW7 expression in cancer tissue tended to be lower than that in adjacent noncancerous tissue (original magnification, 
100×). (B) FBXW7 expression at the cancer invasion front was lower than that in the primary tumor (original magnification, 40×). (C) A 
representative sample of high FBXW7 expression (original magnification, 200×). (D) A representative sample of low FBXW7 expression 
(original magnification, 200×). All scar bars are 100 µm.
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cells was dependent on MCL1 accumulation, we 
suppressed MCL1 expression using MCL1-specific 
siRNA in FBXW7-knockdown cells. MCL1 suppression 
was confirmed by western blotting (Figure 4A). Enhanced 
chemoresistance to gemcitabine and nab-paclitaxel in 
FBXW7-knockdown cells was eliminated by MCL1 
suppression (Figure 4B, 4C). 
DISCUSSION
Here, we demonstrated that low FBXW7 expression 
in pancreatic cancer tissue was associated with cancer 
progression and was an independent factor predicting poor 
prognosis. Additionally, an inverse relationship between 
FBXW7 and MCL1 or Ki-67 expression was observed 
Figure 2: Survival curves according to FBXW7 expression in pancreatic cancer. All survival curves were obtained using the 
Kaplan-Meier methods. (A, B) Overall survival rates and cancer-specific survival rates. (C) Relapse-free survival rates. (D) Prognosis in 
relation to gemcitabine treatment after surgery or recurrence in the low and high FBXW7 expression groups.
Table 2: Univariate and multivariate analyses of variables related to overall survival, as determined 
using Cox proportional hazards models
Variables
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age (< 70 vs. ≥ 70) 1.02 0.66–1.57 0.899 − − −
Sex (Male vs. Female) 0.93 0.61–1.44 0.774 − − −
Histological type (Well vs. Moderately, 
Poorly) 2.09 1.06–4.76 0.031* 1.05 0.56−2.20 0.881
T factor (UICC) (T1, 2 vs. T3, 4) 3.89 1.61–12.82 0.001* 1.80 0.62−7.66 0.306
Lymph node metastasis (Absent vs. 
Present) 1.19 0.72–2.06 0.505 − − −
Venous invasion (v0,1 vs. v2,3) 2.53 1.61–4.07 < 0.0001* 2.52 1.50−4.40 0.003*
Lymphatic invasion (ly0,1 vs. ly2,3) 1.52 099–2.35 0.053 − − −
Perineural invasion (ne0,1 vs. ne2,3) 1.39 0.86–2.33 0.176 − − −
FBXW7 (High vs. Low) 1.78 1.14–2.79 0.011* 1.66 1.03−2.66 0.039*
Abbreviations: HR, hazard ratio; CI, confidence interval; UICC, Union for International Cancer Center.
*p < 0.05.
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by immunohistochemistry. Moreover, among patients 
with gemcitabine treatment, those in the low FBXW7 
expression group showed significantly shorter overall 
survival than those in the high FBXW7 expression group, 
suggesting that FBXW7 may mediate chemoresistance. In 
our in vitro analysis, we found that knockdown of FBXW7 
enhanced cell proliferation, migration, and invasion 
abilities, and decreased sensitivity to gemcitabine and 
nab-paclitaxel in pancreatic cancer cells. Furthermore, the 
decreased chemosensitivity in FBXW7-knockdown cells 
was recovered by MCL1 suppression, suggesting that 
reduced FBXW7 levels enhanced chemoresistance via 
accumulation of the anti-apoptotic protein MCL1.
In previous studies, low expression of FBXW7 
in cancer tissue was found to be associated with poor 
prognosis and cancer progression in several solid 
cancers, including gastric cancer [9], colorectal cancer 
[11], esophageal cancer [10, 18], non-small cell 
lung cancer [19], cholangiocarcinoma [12, 13], and 
hepatocellular carcinoma [20]. These results suggested 
that FBXW7 status in cancer tissue may be a potential 
prognostic marker. In our study, low FBXW7 expression 
was significantly associated with venous invasion and 
poor prognosis and was therefore an independent factor 
predicting poor prognosis. Thus, FBXW7 expression 
in pancreatic cancer may be a promising prognostic 
Figure 3: In vitro functional analysis of FBXW7 in SUIT-2 pancreatic cancer cells transfected with FBXW7-specific 
siRNA. (A) FBXW7 and MCL1 expression levels in SUIT-2 cells transfected with FBXW7-specific siRNA were evaluated by western 
blotting. β-actin was used as the internal control. (B) Cell proliferation ability of SUIT-2 cells transfected with FBXW7-specific siRNA was 
analyzed using CCK-8 assays. (C) Cell migration ability of the FBXW7-specific siRNA group was evaluated by wound healing assays. (D) 
Cell invasion ability of the FBXW7-specific siRNA group was evaluated by Matrigel invasion assay. (E, F) Cell viabilities after 48 h of 
treatment with gemcitabine and nab-paclitaxel were evaluated using CCK-8 assays. FBXW7 knockdown cells revealed enhanced resistance 
to both gemcitabine and nab-paclitaxel compared with control cells. CCK-8, Cell Counting Kit-8; *P < 0.05.
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marker, consistent with previous reports in other 
cancers.
FBXW7 regulates various proteins, including 
c-Myc, cyclin E, mTOR, c-Jun, MCL1, and Notch, via 
the ubiquitin-proteasome system [6, 21]. In previous 
studies, these proteins were reported as oncoproteins 
whose overexpression is associated with poor prognosis, 
aggressive proliferation, migration, invasion, and 
metastatic potential in various cancers [22–24]. Moreover, 
a recent study showed that β-catenin, which regulates 
the Wnt signaling pathway and is related to pancreatic 
cancer malignancy, is a target of FBXW7 [25]. Thus, 
these data suggested that low expression and/or loss of 
function of FBXW7 leads to accumulation of various 
oncoproteins and activation of the Wnt signaling pathway 
via β-catenin accumulation, suggesting that FBXW7 
regulates the malignant potential of cancers, including 
pancreatic cancer. In the present study, we demonstrated, 
for the first time, that the proliferative activity of cells in 
pancreatic cancer samples with low FBXW7 expression 
was enhanced and that the degree of venous invasion in 
cells with low FBXW7 expression was more advanced 
compared with that in cells with high FBXW7 expression. 
Furthermore, we validated that FBXW7 suppression 
using siRNA enhanced cells proliferation, migration, and 
invasion abilities in vitro. Recently, Jin and colleagues 
demonstrated that FBXW7 suppresses enhancer of zeste 
homolog 2 (EZH2) activity and inhibits tumor migration 
and invasion via degradation of EZH2 in pancreatic 
cancer cells [26]. Thus, since FBXW7 mediates diverse 
proteins that regulate malignant potential, such as tumor 
proliferation, migration, and invasion, which are important 
for pancreatic cancer progression, FBXW7 induction may 
be a novel therapeutic strategy to suppress pancreatic 
cancer development and progression.
As previously described, FBXW7 regulates the 
degradation of several oncoproteins related to the not only 
tumor aggressiveness but also therapeutic resistance [19, 
27–29]. MCL1 is an important target substrate of FBXW7 
and is associated with apoptosis [16]. In previous studies, 
elevated MCL1 levels were found to induce resistance to 
antitubulin therapies, such as paclitaxel and vincristine 
[17, 19], and MCL1 gene silencing induced apoptosis and 
increased chemosensitivity to gemcitabine in pancreatic 
cancer [30]. Recently, nab-paclitaxel, new antitubulin 
agent, has been added to some chemotherapy regimens for 
the treatment of pancreatic cancer [3, 31]. Additionally, 
gemcitabine has been used as a key drug for the treatment 
of pancreatic cancer for many years [32]. Thus, MCL1, 
which is associated with sensitivity to both antitubulin 
therapy and gemcitabine, is an important protein 
mediating chemoresistance in pancreatic cancer. In the 
present study, we found an inversed relationship between 
FBXW7 and MCL1 expression in clinical samples and 
showed that FBXW7 suppression decreased sensitivity to 
both gemcitabine and nab-paclitaxel and elevated MCL1 
protein levels in vitro. Additionally, we showed that the 
decreased sensitivity to both agents induced by FBXW7 
suppression was recovered by MCL1 suppression. These 
results revealed that MCL1 may be a key protein involved 
Figure 4: Enhanced chemoresistance in FBXW7-knockdown cells was eliminated by MCL1 suppression. (A) MCL1 
suppression was evaluated by western blotting. β-actin was used as the internal control. (B, C) Cell viabilities after 48 h of treatment with 
gemcitabine and nab-paclitaxel were evaluated using CCK-8 assays. Enhanced chemoresistance to gemcitabine and nab-paclitaxel in 
FBXW7-knockdown cells was eliminated by MCL1 suppression CCK-8, Cell Counting Kit-8; *P < 0.05.
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in chemoresistance induced by FBXW7 knockdown in 
pancreatic cancer cells. Furthermore, in pancreatic cancer 
clinical samples, among patients who received gemcitabine 
treatment as adjuvant therapy or after recurrence, the 
overall survival rate was significantly lower in the low 
FBXW7 expression group than in the high FBXW7 
expression group. This suggested that the poor prognosis 
in patients with low FBXW7 expression may be caused 
by chemoresistance. Although we could not evaluate 
the relationship between FBXW7 expression and nab-
paclitaxel efficacy because there was no nab-paclitaxel 
treatment group in this study, we expect that tumors will 
be refractory to nab-paclitaxel treatment in patients with 
low FBXW7 expression. Thus, FBXW7 expression status 
in cancer tissue may be a predictive marker of standard 
chemotherapy for pancreatic cancer. The present study 
is the first report demonstrating an association between 
FBXW7 expression and chemosensitivity in pancreatic 
cancer. Although chemotherapeutic resistance in 
pancreatic cancer is a serious problem and occurs through 
various molecular pathways [33], our data showed that 
FBXW7 and its substrate MCL1 are important factors 
involved in chemotherapeutic resistance and are expected 
to be candidate therapeutic targets for overcoming 
therapeutic resistance.
In conclusion, we found that FBXW7 expression 
levels in primary tumor tissues could predict prognosis 
in patients with pancreatic cancer. In addition, reduced 
FBXW7 expression enhanced tumor cell proliferation, 
migration, and invasion and the sensitivity of pancreatic 
cancer cells to gemcitabine and nab-paclitaxel was 
regulated by FBXW7 via MCL1 accumulation. These 
results suggested that evaluation of FBXW7 expression 
may be a promising prognostic marker and that the 
FBXW7/MCL1 axis may be employed as a therapeutic 
tool to overcome refractory pancreatic cancer. 
MATERIALS AND METHODS
Clinical samples
Primary pancreatic cancer tissues were obtained 
from 122 patients with pancreatic cancer who underwent 
curative surgical resection at the Department of Gunma 
University Hospital (Maebashi, Japan) and Saiseikai 
Maebashi Hospital (Maebashi, Japan) between 1999 and 
2012. There were 66 men and 56 women, and the median 
age was 67.4 years (range, 36–87 years). There were no 
patients who had received neoadjuvant chemotherapy or 
irradiation prior to surgical resection. Ninety-eight patients 
received adjuvant chemotherapy by gemcitabine, tegafur/
gimeracil/oteracil (S-1), or tegafur-uracil. Recurrence was 
observed in 89 patients. A total of 95 patients received 
gemcitabine as adjuvant chemotherapy or to treat 
recurrence. The tumor stages were classified according 
to the Seventh Edition of the Tumor-Node-Metastasis 
Classification of the Union for International Cancer Center 
and the Sixth General Rules for the Study of Pancreatic 
Cancer of Japan Pancreas Society. All clinical samples 
and patient data were analyzed in accordance with our 
institutional guidelines and the Declaration of Helsinki 
after obtaining written informed consent from all patients.
Immunohistochemical staining and evaluation
The resected surgical specimens were fixed 
with 10% formaldehyde and embedded in paraffin 
blocks. The blocks were cut into 2-µm thick sections 
and mounted on glass slides. The staining protocol 
was carried out by standard methods, as described 
previously [34]. The sections were incubated overnight 
at 4°C with rabbit anti-FBXW7 antibodies (ab109617; 
dilution, 1:300; Abcam, Cambridge, MA, USA), rabbit 
anti-MCL1 monoclonal antibodies (ab32087, 1:1000; 
Abcam), or mouse anti-Ki-67 antibodies (M7240; 
dilution, 1:150; Dako; Agilent Technologies, Santa 
Clara, CA, USA) as primary antibodies. Each section 
was counterstained with Mayer’s hematoxylin solution 
and mounted. A negative control was established by 
replacing the primary antibody with phosphate-buffered 
saline (PBS) in 0.1% bovine serum albumin, and no 
detectable staining was observed.
Assessment of FBXW7 expression was performed 
as described previously [13]. The expression of nuclear 
FBXW7 was scored according to the proportion and 
intensity of staining in five randomly selected fields. 
We evaluated nuclear FBXW7 expression in the central 
portion of the tumor, because FBXW7 expression at 
the cancer invasion front tended to be lower than that 
at the center of the tumor. The scores for the proportion 
of stained tumor cell area were as follows: 1, < 10%; 
2, 10–50%; 3, > 50%. The scores for the intensity of 
nuclear staining were as follows: 1, weak; 2, moderate; 
3, strong. The final score used in analysis was defined 
by multiplying the proportion score and intensity score, 
with a maximum score of 9. We defined the optimal 
cut-off point as follows: a final score of less than 4 was 
considered low expression, whereas a score of 4 or more 
was considered high expression. MCL1 expression was 
evaluated as low (< 25%) or high (≥ 25%) according to 
the proportion of positive tumor cells [35]. The expression 
of Ki-67 was evaluated by calculating the positive cells in 
1000 tumor cells for each sample [36]. All images were 
obtained from a fluorescence microscope (BZ-X700; 
KEYENCE, Osaka, Japan).
Cell culture
The human pancreatic cancer cell line SUIT-2 was 
used in the present study. SUIT-2 cells were obtained from 
JCRB Cell Bank (Osaka, Japan). The cells were cultured 
in Dulbecco’s modified Eagle medium (Wako, Osaka, 
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Japan) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin (Thermo Fisher Scientific, 
Kanagawa, Japan) and maintained at 37°C in a humidified 
5% CO2 incubator.
RNAi of FBXW7
FBXW7-specific siRNA (ON-TARGETplus 
SMARTpool) and nontargeted control siRNA (ON-
TARGETplus Non-targeting Pool) were purchased from 
Dharmacon GE Healthcare (Buckinghamshire, UK). 
MCL1-specific siRNA was purchased from Thermo Fisher 
Scientific (Silencer Select siRNA). SUIT-2 cells were 
suspended at a density of 1.0 × 106 cells in 100 µL Opti-
MEM I Reduced Serum Media (Thermo Fisher Scientific) 
and then mixed with FBXW7-specific siRNA, MCL1-
specific RNA, or nontargeted control siRNA as a negative 
control. Transfection with siRNA was performed using 
a CUY21 EDIT II electroporator (BEX, Tokyo, Japan), 
with poring and transfer pulses applied at 150 and 10 V, 
respectively. Subsequent assays were conducted between 
24 and 96 h after transfection.
Protein extraction and Western blotting
Total protein was extracted from transfected 
SUIT-2 cells using RIPA Buffer (Wako) according to 
the manufacturer’s protocol. Extracted proteins were 
separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis with 10% TGX gels (Bio-Rad, 
Hercules, CA, USA) and transferred to nitrocellulose 
membranes by the wet transfer method. The membranes 
were blocked with 5% skim milk and then incubated 
at 4°C overnight with anti-FBXW7 rabbit monoclonal 
antibodies (ab171961; 1:1000; Abcam) or anti-MCL1 
rabbit monoclonal antibodies (ab32087; 1:1000; 
Abcam); anti-β-actin mouse monoclonal antibodies 
(A5316; 1:1000; Sigma, St. Louis, MO, USA) were 
used as an internal control. The membranes were 
then treated with horseradish peroxidase-conjugated 
secondary antibodies. Protein bands on the membrane 
were detected using ECL Prime Western Blotting 
Detection Reagent and an Image Quant LAS4000 (GE 
Healthcare).
Cell proliferation assays
The proliferation ability of siRNA-transfected 
SUIT-2 cells was analyzed using a Cell Counting Kit-
8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan). 
SUIT-2 cells were seeded at a density of 2000 cells/well 
in 96-well plates with 100 µL medium containing FBS. 
Cell proliferation was evaluated at initial seeding (0 h) and 
at 24, 48, and 72 h. The reagent was added at a volume 
of 10 μL/well, and cells were incubated at 37°C for 2 
h. The absorbance of each well was measured using an 
Absorbance Spectrophotometer (Bio-Rad) at 450 nm with 
the reference wavelength set at 650 nm. 
Wound healing assay
Cell migration ability was evaluated in siRNA-
transfected SUIT-2 cells using wound healing assays. 
The cells were seeded in 24-well plates and cultured until 
reaching confluence. Then, a uniform straight wound 
was generated in each using a pipette tip. Each well was 
washed with PBS to remove all cell debris, and the cells 
were cultured at 37°C for 48 h. Closure or filling in of the 
wound was evaluated.
Invasion assay
Cell invasion assay was performed using 24-well 
Corning BioCoat Matrigel Invasion Chambers (Corning, 
NY, USA). Transfected SUIT-2 cells (1 × 105 cells) with 
500 µL of medium were seeded in the upper chamber, 
and the lower chamber was filled with 750 µL of medium 
containing 10% FBS as a chemoattractant. After a 48 h 
incubation, the cells were fixed and stained with Diff-Quik 
(Sysmex Corporation, Kobe, Japan). After staining, the 
cells which invaded through the pores to the lower surface 
of the membrane were counted by microscopy. A total of 
10 randomly selected fields were evaluated.
Drug sensitivity assay
Gemcitabine (Selleck Chemicals, Houston, TX, 
USA) and nab-paclitaxel (Taiho Pharmaceutical, Tokyo, 
Japan) sensitivities were evaluated using siRNA-transfected 
SUIT-2 cells. The cells were seeded at a density of 1 × 104 
cells/well in 96-well plates with 100 µL medium. After 
24 h, the cells were treated with various concentrations of 
gemcitabine (0, 1, 5, 50, or 100 nM) and nab-paclitaxel (0, 
0.1, 1, 5, or 10 µM) for 48 h. Cell viability was evaluated 
using CCK-8 assays (Dojindo Laboratories), as described 
above. The absorbance of each well was measured using 
an Absorbance Spectrophotometer at 450 nm with the 
reference wavelength set at 650 nm.
Statistical analysis
Data for continuous variables were expressed 
as median and range. Statistical significance was 
analyzed using Mann-Whitney U tests for continuous 
variables and chi-squared tests for categorical variables. 
Survival curves were described using the Kaplan-Meier 
method, and differences in survival between groups 
were compared using the log-rank test. Univariate 
and multivariate analyses were performed using Cox 
proportional hazards models and were used to analyze 
the prognostic factors. Results with P values of less 
than 0.05 were considered statistically significant. 
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All statistical analyses were conducted using the JMP 
software package (version 13.0.0; SAS Institute Inc., 
Cary, NC, USA).
Abbreviations
FBXW7: F-box and WD repeat domain-containing 
7, EZH2: enhancer of zeste homolog 2, CCK-8: Cell 
Counting Kit-8, PBS: phosphate-buffered saline, FBS: 
fetal bovine serum, RNAi: RNA interference.
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